Thursday, November 19, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 54

Sanofi's next-gen rabies shot VaxRabeo scores EU approval

Sanofi won European Commission approval for VaxRabeo, a next-generation rabies vaccine cleared for pre- and post-exposure use in all age groups in the EU. It follows a US FDA nod for Infilbray in Type 3 Gaucher disease. Shares closed at €86.25, but one Simply Wall St community narrative pegs fair value at €72.23 — roughly 19% below where Sanofi trades.

By the Paparazzi desk November 19, 2026 · 3:16 AM · finance.yahoo.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: finance.yahoo.com.
  • The source published it on Nov 19, 2026 at 3:16 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

Sanofi just picked up European Commission approval for VaxRabeo, a next-generation rabies vaccine cleared for both pre-exposure and post-exposure use in every age group across the EU. It's the French drugmaker's second regulatory win in a short stretch.

The other came from the US FDA, which green-lit Infilbray for Type 3 Gaucher disease. Sanofi is also preparing for a leadership change in R&D starting January 2027.

Sponsored

The stock has been moving. Sanofi last closed at €86.25, with a 30-day share price return of 21.46% and a 90-day return of 10.88%, even as the 1-day return slipped slightly. Over longer horizons, the 1-year total shareholder return sits at 5.97% and the 5-year at 22.40%.

Not everyone is convinced the price matches the progress. A community narrative on Simply Wall St written by investor Szock sets fair value at €72.23, which would make Sanofi about 19% overvalued at its current level. Szock frames the company as a mix of valuation appeal, income and operational momentum, noting the shares traded in a range of roughly €76 to €77 in recent months and sit well below earlier highs.

The bull case rests on expectations that analysts set fair value noticeably higher and a moderate price-to-earnings ratio on forecast profits. The bear case has teeth too: the narrative cracks if key drugs meet faster-than-expected competition or if regulatory setbacks slow the pipeline.

TopicsSanofi · VaxRabeo · Infilbray · European Commission · US FDA · Simply Wall St · Szock · ENXTPA:SAN

Share

Source: finance.yahoo.com

Written by AI from verified reporting.

More stories

  • Health & science 11:45 UTC · 1 hour ago · reuters.com · Caught by @mimi💕💕 · 1 view
    AbbVie Bets Up to $2.54B on Disco's Next-Gen Cancer Drugs
  • Health & science 11:45 UTC · 1 hour ago · fnob.it · 1 view
    TenK10K maps 5 million immune cells, linking DNA variants to 16 diseases
  • Health & science 11:12 UTC · 2 hours ago · trtworld.com · Caught by @pz09253 · 0 views
    France lifts bird flu alert to maximum level across mainland
  • Health & science 07:31 UTC · 5 hours ago · news24.com.au · 0 views
    Actinogen trial: Alzheimer's drug slows decline by 30pc in over-75s
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.